UPDATE: Immunic Inc. (IMUX) Announces Positive Top-Line Data from Phase 2 EMPhASIS Trial of IMU-838 in Patients with Relapsing-Remitting MS

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/20/2026

1. SPY
2. XENE
3. HUBS
4. NUE
5. RTB
6. ONON
7. AAPL
8. ACN
9. AZN
10. SPCX

Go back to UPDATE: Immunic Inc. (IMUX) Announces Positive Top-Line Data from Phase 2 EMPhASIS Trial of IMU-838 in Patients with Relapsing-Remitting MS
(NASDAQ: IMUX) Delayed: 10.62 +0.27 (2.61%)
Previous Close $10.35    52 Week High $ 
Open $10.30    52 Week Low $ 
Day High $10.74    P/E N/A 
Day Low $10.21    EPS $ 
Volume 404,000